(Reuters) -The U.S. health regulator said on Wednesday it has approved the expanded use of Bristol Myers Squibb’s cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments.
The Food and Drug Administration’s decision marks the fourth approval for Breyanzi. It was first approved in the United States in 2021 as a second-line treatment for a type of blood cancer known as large B-cell lymphoma.
The therapy belongs to a class of drugs known as chimeric antigen receptor (CAR) T-cell therapies that work by modifying white blood cells known as T-cells to attack cancer.
(Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
